Skip to content
Clinical Trials – home

DKD HELIOS Klinik Wiesbaden GmbH

Verified siteinfo

Germany Aukammallee 33, Bierstadt, 65191 Wiesbaden, Germany

  • 3 trials recruiting
  • Multiple sclerosis · Chronic kidney disease · Nervous system disorder
  • Adult patients

About Specializations

DKD HELIOS Klinik Wiesbaden GmbH in Wiesbaden, Germany specialises in clinical trials of conditions such as Multiple sclerosis, Chronic kidney disease, Nervous system disorder, Primary progressive multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular and Kidney Research

At DKD HELIOS Klinik Wiesbaden GmbH, clinical trials in cardiovascular disease and kidney disease focus on conditions such as chronic kidney disease and uncontrolled hypertension. These studies are designed to assess new treatment strategies that may help protect kidney function, reduce heart-related complications, and improve blood pressure control.

  • Chronic kidney disease and combined kidney-heart outcome research
  • Hypertension studies aimed at better blood pressure management
  • Trials evaluating therapies to lower the risk of kidney failure, hospitalization for heart failure, and mortality

This area reflects a strong interest in improving long-term outcomes for patients living with complex cardiorenal conditions.

Neurology and Multiple Sclerosis

A major part of the research portfolio at this site centers on nervous system diseases, especially multiple sclerosis in its relapsing, progressive, and primary progressive forms. The trials are exploring ways to improve symptom control, slow disability progression, and better understand the patient experience of living with these conditions.

  • Studies in relapsing multiple sclerosis and progressive multiple sclerosis
  • Research on primary progressive multiple sclerosis and treatment effectiveness
  • Trials assessing patient-reported impact and continued access to therapy

The site also contributes to research on broader neurological disease management, including efforts to maintain access to ongoing treatment for eligible participants.

Movement Disorders and Symptom Relief

Research in this therapeutic area includes studies on Parkinson's disease and lower limb spasticity, with a focus on easing motor symptoms and improving daily function. These trials are intended to test therapies that may reduce tremor, stiffness, and movement-related impairment.

  • Parkinson's disease studies targeting residual tremor
  • Trials for lower limb spasticity linked to neurological injury
  • Work aimed at improving functional ability and symptom control

This research supports better care for patients whose neurological conditions affect mobility and everyday activities.

Autoimmune and Headache Disorders

The site also participates in studies within immune system diseases, including generalized myasthenia gravis, as well as research on migraine. These trials are evaluating new ways to reduce disease burden, improve symptom relief, and support better day-to-day functioning.

  • Generalized myasthenia gravis treatment research
  • Migraine studies focused on acute symptom relief
  • Trials testing therapies intended to improve quality of life and daily performance

Together, these studies show a broad interest in both chronic autoimmune conditions and common neurological pain disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Aukammallee 33, Bierstadt65191 WiesbadenGermany
Recruiting now
3 trials
Conditions studied
12
Partner status
Verified site

More sites in WiesbadenGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Nervous system disorder

Not yet recruiting

Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hypertension

Not recruiting

Study on Lorundrostat for Patients with Uncontrolled and Resistant Hypertension

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lorundrostat
  • Sponsor:Mineralys Therapeutics Inc.

Multiple sclerosis+1

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Paresis

Not recruiting

Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Pharmaceuticals GmbH

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.